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Purpose/Objective: Patients (pts) with locally advanced soft 
tissue sarcoma of the extremities or trunk wall are frequently 
treated with neo-adjuvant treatment followed by wide 
resection. Pre-operative radiotherapy (RT) is one of these 
validated options. To optimize outcome, NBTXR3, 
functionalized hafnium oxide nanoparticles, have been 
developed as selective radioenhancer, which may represent a 
breakthrough approach for the local treatment of solid 
tumors. The high electron density of NBTXR3 nanoparticles 
when exposed to radiotherapy, may allow 
absorption/deposition of a high energy dose within the 
cancer cell, and possibly improve outcome. 
Materials and Methods: Pts received a single intratumor (IT) 
injection of NBTXR3 at fixed concentration (53.3 g/L), 
volume escalated from level 1 (2.5% of tumor volume) to 
level 4 (20% of tumor volume), followed by RT (50 Gy in 25 
fractions of 2 Gy over 5 weeks). Primary endpoints include 
feasibility of the IT implantation and safety. Secondary 
endpoints focus on efficacy such as pathological and RECIST 
response, IT residency of NBTXR3 over the whole RT time, 
and operability. 
Results: Out of 21 pts included, 20 are evaluable: they 
underwent a wide surgical resection and received the 
planned radiotherapy. Feasibility of the IT injection was 
confirmed. The treatment was safe. Main grade 1-2 toxicities 
related to NBTXR3 were injection pain/reaction (4 pts), fever 
(2 pts), abdominal pain (1 pt), pruritus (1 pt) and paresthesia 
(1 pt). At volume 20%, 2 pts had grade 3 pain at the injection 
site. Results demonstrate that one injection of NBTXR3 
provides adequate bioavailability of NBTXR3 over five weeks 
of radiotherapy. No leakage of NBTXR3 to the adjoining 
healthy tissues was observed. Further, NBTXR3 persistence 
was established by CT scan before surgery. At Volumes 
2.5%,5%,10%, and 20%, the median change in sarcoma volume 
was respectively 13%; 40%, 44% and 51%. The percentage of 
residual and viable cells was 34% at the chosen maximum 
tolerated 10% level of tumour volume.  
Conclusions: Injection of NBTXR3 was very well tolerated 
until 10% of tumor volume. NBTXR3 with preoperative RT 
seems to be an effective neo-adjuvant treatment for pts with 
locally advanced STS. An international phase II/III will start in 
the Q4 2014. The recommended volume is 10% of tumor 
volume, for this prospective study comparing this 
investigational treatment to pre-operative RT  
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Purpose/Objective: The role of pelvic elective nodal 
irradiation (ENI) in the management of prostate cancer is still 
controversial. Despite negative clinical trials, clinical 
practices vary greatly, even in patients at high risk of pelvic 
lymph node dissemination. The aim of this study was to 
analyze the role of pelvic radiotherapy on the outcome in 
high-risk localized prostate cancer patients included in the 
recently reported GETUG 12 trial (Fizazi et al, ASCO 2014). 
Materials and Methods: Eligibility criteria included non-
pretreated high-risk localized CaP, defined as one or more of 
the following criteria: T3-T4, Gleason score (GS)>7, PSA>20 
ng/mL, pN+ (stratification factors). All pts had a staging 
pelvic lymph node dissection. Pts were randomly assigned to 
either goserelin 10.8 mg every 3 months for 3 years and 4 
cycles of docetaxel 70 mg/m2 q3w + estramustine 10 
mg/kg/d d1-5 (ADT+DE arm) or goserelin alone (ADT arm). 
Local therapy was administered 3 months after the start of 
hormonal treatment. The performance of pelvic ENI was left 
to the treating physician and was performed using 3D 
conformal radiotherapy. Median dose was 46 Gy in 2 Gy 
fractions. Only patients treated with primary radiotherapy 
are included in this analysis. Multivariate Cox model was used 
to look for an association between pelvic ENI and biochemical 
progression free survival (bPFS). Adjustment factors were: 
PSA level, T stage, Gleason score, pN stage. 
Results: 413 patients were included from 2002 to 2006, out 
of which 358 were treated using primary radiotherapy and 
are analyzed in the present report. 208 patients received a 
pelvic radiotherapy and 150 prostate-only. PSA level, Gleason 
score or T stage did not differ according to the performance 
of pelvic radiotherapy. However pN+ patients more 
frequently received pelvic radiotherapy than pN0 patients 
(pelvic ENI 89% in pN+ pts and 47% in pN0 pts; p 
Conclusions: This unplanned analysis of a recently completed 
trial failed to demonstrate a benefit of pelvic radiotherapy in 
high-risk localized prostate cancer patients. bPFS was 
negatively impacted by pN+ and positively impacted by 
chemotherapy in GETUG 12 patients treated by radiotherapy.  
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Purpose/Objective: To report the grade 3 and higher (G3+) 
GU and GI toxicity for patients in a randomized trial 
evaluating the efficacy and safety of two different 
techniques for achieving dose escalation. 
Materials and Methods: 398 men with National 
Comprehensive Cancer Network (NCCN) intermediate-risk 
(N=122) or high-risk (N=276) localized prostate cancer were 
accrued at 6 centers, stratified by risk group and randomized 
to one of two treatment arms. Both arms received 12 months 
of androgen deprivation therapy (ADT via LHRH depot 
injections), 8 months of which was given prior to starting 
whole pelvic irradiation (46Gy/23/#s). Patients randomized 
to the dose-escalated external beam arm (DE-EBRT, N=200) 
continued with a 3-d conformal boost to the prostate of 
32Gy/16#s. Patients randomized to the low-dose-rate 
Brachytherapy arm (LDR-PB, N=198) had an 125Iodine implant 
(MPD = 115Gy). Physician-scored toxicity was prospectively 
assessed and recorded using a modified LENT-SOMA scoring 
system. Follow up (FU) times for the toxicity data was 
calculated from the date of the start of Radiation treatment. 
The primary endpoint of the trial was disease free survival 
(DFS). There were 12 major protocol violations in each arm; 
all results are reported on an intent-to-treat basis. 
Results: Patients randomized to LDR-PB were more than 
twice as likely to be disease-free at median FU of 6.5 yrs 
(hazard ratio = 2.11; 95% CI 0.1.31 – 3.42; P = 0.0022). Acute 
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G3+ GU toxicity was observed in 1% of DE-EBRT and 2.5 % of 
LDR-PB arms. No acute G3+ GI toxicity was observed. The 
cumulative incidence of late G3+ GU toxicity at 2 and 6 years 
was 4% and 8% in DE-EBRT versus 8% and 18% LDR-PB 
respectively (p<0.0001). Urethral strictures requiring 
dilatation, urinary retention requiring a TURP or TUIP, and 
severe urinary incontinence were the most common G3+ GU 
events and were all significantly less common with DE-EBRT 
at 1%, 1% and 0% compared to LDR-PB at 7.5%, 3%, and 2.5%. 
The prevalence of G3+ GU toxicity at 2 and 6 years with DE-
EBRT was 1.6% and 1.1% versus 5.4% and 4.7% with LDR-PB. 
The cumulative incidence of late G3+ GI toxicity at 2 and 6 
years was 3% and 4% with DE-EBRT versus 3% and 9% with 
LDR-PB respectively (p=0.07). Grade 3 rectal bleeding and 
fecal incontinence were observed in 3.5% and 0% of DE-EBRT 
patients versus 3.0% and 1.5% with LDR-PB. The prevalence of 
G3+ GI toxicity at 2 and 6 years with DE-EBRT was 2% and 0% 
versus 1.0% and 0% with LDR-PB. 
 
Conclusions: GI toxicity did not differ significantly between 
arms, but the cumulative incidence of late G3+ GU toxicity 
was 18% with LDR-PB versus 8% with DE-EBRT. Since many 
toxicity events were temporary and others were reversed or 
ameliorated by urologic procedures, the long term 
prevalence of G3+ GU toxicity with LDR-PB is much lower 
than the incidence rate. 
*ASCENDE-RT- Androgen Suppression Combined with Elective 
Nodal and Dose Escalated Radiation Therapy is an NCI 
registered trial (NCT00175396). 
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Purpose/Objective: Modern diagnostic imaging gives high-
resolution anatomical detail enabling detection of tumour 
deposits measuring only a few millimetres. As a consequence, 
it is plausible that the occult tumour-load in what we 
currently identify as the 'elective volume' is much less than 
before. Therefore, dose reduction to elective lymph node 
regions is increasingly becoming a topic of interest in 
radiation therapy (RT) for head and neck cancer, in order to 
reduce acute and late radiation sequelae. The aim of this 
study is to provide insight in patterns of recurrence in 
electively irradiated lymph node regions after intensity-
modulated radiation therapy (IMRT) for head and neck 
cancer. 
Materials and Methods: A total of 264 patients having stage 
cT2-4N0-2M0 squamous cell carcinoma of the oropharynx, larynx 
or hypopharynx treated with curative intent using 
accelerated IMRT between 2008-2011 were included. 
Excluded were patients treated with surgery or 
chemotherapy. Median follow-up is 2.7 years. RT planning 
CT-scans from all patients were reviewed and all lymph 
nodes (short -axis diameter ≥5mm and ≤10mm) localized in 
the elective volume were identified and delineated. For each 
node, we measured volume, long- and short-axis diameter. 
The exact sites of regional recurrences were reconstructed 
and projected on the initial RT treatment planning CT-scan 
by performing co-registration with diagnostic imaging of the 
recurrence. 
Results: Actuarial rate of recurrence in electively irradiated 
lymph node regions was 5.1% (95% CI:2.4-7.8%) at 2 years.  
On the RT planning CT-scans, 1166 electively irradiated 
lymph nodes (short -axis diameter ≥5mm and ≤10mm) were 
identified. Volumetric analysis showed an increased risk of 
recurrence with increasing nodal volume, up to 19.4% (95% 
CI:5.1-33.7%) at 3 years for lymph nodes >1.5cc. The summed 
long- and short-axis diameter showed to be a pragmatic 
alternative for the more laborious volume calculations, 
having an optimal combination of sensitivity (88%) and 





Figure 1: Recurrence in electively irradiated lymph nodes 
according to summed short- and long-axis diameter 
Univariate analysis: <17mm versus ≥17mm (p<0.001)  
Conclusions: This is the first study focussing on recurrences 
in electively irradiated lymph nodes in a large and 
homogeneous population after definitive IMRT. Important 
risk-factors were identified that can help clinicians in the 
pre-treatment risk-assessment of borderline-sized lymph 
nodes. Not overtly pathologic lymph nodes having a summed 
diameter ≥17mm may require an intermediate RT dose. For 
low-risk elective areas (all nodes <17mm), de-escalation 
below the traditional 50Gy can be considered.  
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